Antiatherosclerotic and antihyperlipidemic effects of octimibate sodium in rabbits.
Octimibate sodium (8-[(1,4,5-triphenyl-1H-imidazol-2-yl)oxy]octanoic acid, sodium salt; NAT 04-152) was investigated for its antihyperlipidemic and antiatherosclerotic activities in New Zealand White rabbits. Hypercholesterolemia and atherosclerosis were induced by feeding a diet containing 0.3% cholesterol for 8 weeks. In addition, repeated injections of bovine serum albumin (BSA) were used to enhance the experimental atherosclerosis. Octimibate sodium, 10.0 and 30.0 mg/kg p.o., reduced both the increase in serum cholesterol levels and the aortic plaque-formation (by about 50% in the higher dose group) as compared to control animals. Serum triglyceride levels were not influenced. Biochemical and histological examinations of the aortas showed reduced cholesterol contents in the higher dose group and a dose-dependent inhibition of pathological changes in the aortas.
Rücker
W
W
Nattermann Research Laboratories, Cologne, F.R.G.
Prop
G
G
Hüther
A M
AM
D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy*; D002210:Caprylates / Q000627:therapeutic use*; D004036:Diet, Atherogenic; D006937:Hypercholesterolemia / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007093:Imidazoles / Q000627:therapeutic use*; D011817:Rabbits; D012710:Serum Albumin, Bovine; D002785:Sterol O-Acyltransferase / Q000037:antagonists & inhibitors
D002210:Caprylates; D000960:Hypolipidemic Agents; D007093:Imidazoles; D012710:Serum Albumin, Bovine; D002785:Sterol O-Acyltransferase; C031492:octanoic acid; C054659:octimibate